| NCT06432647 | A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105 | COMPLETED | PHASE1 | 2024-04-24 | 2024-11-25 | 2024-11-25 |
| NCT05511558 | A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017) | COMPLETED | PHASE1 | 2022-07-13 | 2022-10-26 | 2022-10-18 |
| NCT05169671 | Safety, Tolerability, and Pharmacokinetics Study of ATH-1020 | COMPLETED | PHASE1 | 2022-03-30 | 2022-09-09 | 2022-09-09 |
| NCT04831281 | ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial) | TERMINATED | PHASE2 | 2022-01-20 | 2023-04-19 | 2023-04-19 |
| NCT04886063 | Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | TERMINATED | PHASE2, PHASE3 | 2021-06-30 | 2024-10-23 | 2024-10-23 |
| NCT04491006 | A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease | COMPLETED | PHASE2 | 2020-11-23 | 2022-05-20 | 2022-05-20 |
| NCT04488419 | ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | COMPLETED | PHASE2, PHASE3 | 2020-09-28 | 2024-07-15 | 2024-07-15 |
| NCT03298672 | Safety, Tolerability, and Pharmacokinetics Study of NDX-1017 | COMPLETED | PHASE1 | 2017-10-09 | 2019-09-05 | 2019-09-05 |